New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis
13 Oktober 2021 - 12:02PM
New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s
Disease-Modifying Therapies Do Not Reduce Antibody Response to
COVID-19 Vaccines in People with Multiple Sclerosis
Biogen Inc. (Nasdaq: BIIB) today announced results of a new
analysis of immune response to the COVID-19 vaccine among people
with multiple sclerosis (MS). The results, which demonstrate that
patients treated with Biogen’s portfolio of MS therapies mount an
effective antibody response to COVID-19 vaccination, are being
presented at the 37th Congress of the European Committee for
Treatment and Research in Multiple Sclerosis (ECTRIMS) virtual
meeting, October 13-15, 2021.
Using data from the MS PATHS network in the U.S., Germany and
Spain, researchers evaluated blood samples from 322 participants
28-90 days after their last COVID-19 vaccine dose. Preliminary
results suggest that anti-CD20 and sphingosine 1-phosphate (S1P)
therapies may reduce the antibody response to COVID-19 vaccination.
For all other classes evaluated in the analysis, including the
broad range of MS therapies offered by Biogen, the antibody
response to vaccination is consistent with the response of patients
not being treated with an MS disease-modifying therapy (DMT).
“These results demonstrate that MS DMTs impact antibody
responses to COVID-19 vaccination in different ways and
understanding these differences is crucial,” said Jeffrey Cohen,
M.D., Cleveland Clinic, and a paid consultant for Biogen. “These
insights are important in helping providers and patients alike
manage MS while seeking to protect patients from COVID-19 through
vaccination.”
Approximately 92 percent of participants in the analysis
received an mRNA vaccine. Immune response was measured using
immunoglobulin G (IgG) assays. Specific IgG rates (IgG index >1)
from initial post-vaccination testing (28-90 days post last
vaccination dose) were 40 percent (32/80) for anti-CD20s
(ocrelizumab, rituximab and ofatumumab), 41 percent (16/39) for S1P
therapies (fingolimod, ozanimod, and siponimod) and 100 percent
(175/175) for all other DMTs (fumarates – dimethyl-fumarate
and diroximel fumarate, glatiramer acetate, interferons – IM IFN
beta-1a, pegylated IFN beta-1a and IFN beta-1b, natalizumab,
teriflunomide and alemtuzumab).
“We care deeply about people with MS and wanted them and their
health care providers to have timely information to help address
key questions about COVID-19,” said Maha Radhakrishnan, M.D., Chief
Medical Officer at Biogen. “Leveraging the unique MS PATHS network,
we were able to quickly generate data on the impact of the
different MS DMTs on COVID-19 vaccine antibody responses. This is
part of a comprehensive plan to understand B and T cell activation
in the context of people with MS on DMTs being vaccinated for
COVID-19 and will add to efforts by researchers to gather these
important data.”
Additional Data Presentations Featured at
ECTRIMSBiogen is presenting a total of 38 abstracts from
across its MS portfolio as part of its ongoing commitment to
improving the understanding of the disease and advancing treatment
through innovation. Presentations at ECTRIMS include:
- IgG Immune Response to SARS-CoV-2 Vaccination in People Living
With Multiple Sclerosis Within MS PATHS (P652)
- Flushing and Flushing-Related Adverse Events With Diroximel
Fumarate in Patients With Relapsing-Remitting Multiple Sclerosis:
Results from the Phase 3 EVOLVE-MS-2 Study (P673)
- Early Data Suggest Diroximel Fumarate Has High Rates of
Real-World Adherence and Persistence (P850)
- Diroximel Fumarate in Patients With Relapsing-Remitting
Multiple Sclerosis: Interim Safety and Efficacy Results from the
Phase 3 EVOLVE-MS-1 Study (P739)
- Comparison of Time to Clinically Meaningful Improvement in
Neuro-QoL in Patients Treated With Natalizumab Versus Ocrelizumab
(P252)
- Comparison of Pharmacokinetic Profiles and Safety
Outcomes with Peginterferon Beta-1a
Administration in Black/African American
and White Participants (P663)
- Efficacy and Safety of Opicinumab in Participants With
Relapsing Multiple Sclerosis: A Randomized, Placebo-Controlled,
Phase 2 Trial (AFFINITY Part 1) (P147)
About MS PATHSBiogen sponsored the MS PATHS
(Partners Advancing Technology and Health Solutions) network to
foster collaboration between leading MS centers in the U.S. and
Europe to help transform patient care by generating standardized
data from a diverse, real-world patient population. MS PATHS is
uniquely able to collect clinical, MRI and biologic data from all
patients in real-time, at the point of care, to better understand
the disease and ultimately improve the lives of those living with
MS.
About BiogenAt Biogen, our mission is clear: we
are pioneers in neuroscience. Biogen discovers, develops and
delivers worldwide innovative therapies for people living with
serious neurological and neurodegenerative diseases as well as
related therapeutic adjacencies. One of the world’s first global
biotechnology companies, Biogen was founded in 1978 by Charles
Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners
Walter Gilbert and Phillip Sharp. Today Biogen has the leading
portfolio of medicines to treat multiple sclerosis, has introduced
the first approved treatment for spinal muscular atrophy,
commercializes biosimilars of advanced biologics and is focused on
advancing research programs in multiple sclerosis and
neuroimmunology, Alzheimer’s disease and dementia, neuromuscular
disorders, movement disorders, ophthalmology, neuropsychiatry,
immunology, acute neurology and neuropathic pain.
We routinely post information that may be important to investors
on our website at www.biogen.com. Follow us on social media
Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe HarborThis news release contains
forward-looking statements, including statements made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, relating to the results of certain real-world
data; the identification and treatment of MS and the effect of our
therapies in relation to COVID-19 vaccination; and our research and
development program for the treatment of MS. These forward-looking
statements may be identified by words such as “aim,” “anticipate,”
“believe,” “could,” “estimate,” “expect,” “forecast,” “goal,”
“intend,” “may,” “plan,” “possible,” “potential,” “will,” “would”
and other words and terms of similar meaning. Drug development and
commercialization involve a high degree of risk, and only a small
number of research and development programs result in
commercialization of a product. Results in early stage clinical
trials may not be indicative of full results or results from later
stage or larger scale clinical trials and do not ensure regulatory
approval. You should not place undue reliance on these statements
or the scientific data presented.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including without limitation the occurrence of
adverse safety events and/or unexpected concerns that may arise
from additional data or analysis; risks of unexpected costs or
delays; failure to protect and enforce our data, intellectual
property and other proprietary rights and uncertainties relating to
intellectual property claims and challenges; product liability
claims; third party collaboration risks; and the direct and
indirect impacts of the ongoing COVID-19 pandemic on our business,
results of operations and financial condition. The foregoing sets
forth many, but not all, of the factors that could cause actual
results to differ from our expectations in any forward-looking
statement. Investors should consider this cautionary statement, as
well as the risk factors identified in our most recent annual or
quarterly report and in other reports we have filed with the U.S.
Securities and Exchange Commission. These statements are based on
our current beliefs and expectations and speak only as of the date
of this news release. We do not undertake any obligation to
publicly update any forward-looking statements, whether as a result
of new information, future developments or otherwise.
MEDIA CONTACT:Ashleigh Koss+ 1 908 205
2572public.affairs@biogen.com |
INVESTOR CONTACT:Mike Hencke+1 781 464 2442IR@biogen.com |
Biogen (TG:IDP)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Biogen (TG:IDP)
Historical Stock Chart
Von Apr 2023 bis Apr 2024